Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1403 Views
-
Last post by NHE
-
- 0 Replies
- 762 Views
-
Last post by NHE
-
- 0 Replies
- 2164 Views
-
Last post by frodo
-
- 0 Replies
- 1044 Views
-
Last post by NHE
-
- 1 Replies
- 979 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1263 Views
-
Last post by frodo
-
- 0 Replies
- 1426 Views
-
Last post by NHE
-
- 0 Replies
- 1993 Views
-
Last post by vesta
-
- 0 Replies
- 1532 Views
-
Last post by frodo